Compare · NVO vs SER
NVO vs SER
Side-by-side comparison of Novo Nordisk A/S (NVO) and Serina Therapeutics Inc. (SER): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SER operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.82B, about 6263.1x SER ($29.4M).
- Over the past year, NVO is down 34.2% and SER is down 64.3% - NVO leads by 30.0 points.
- Both names hit the wire about 5 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 1 for SER).
- Company
- Novo Nordisk A/S
- Serina Therapeutics Inc.
- Price
- $41.18+6.93%
- $1.93-1.53%
- Market cap
- $183.82B
- $29.4M
- 1M return
- +13.32%
- -36.20%
- 1Y return
- -34.24%
- -64.26%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- AMEX
- IPO
- 2018
- News (4w)
- 5
- 5
- Recent ratings
- 25
- 1
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S
Latest SER
- Serina Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form 4 filed by Bailey Gregory
- SEC Form 4 filed by Venkatesan Jay
- SEC Form PRE 14A filed by Serina Therapeutics Inc.
- Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit
- Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan
- Amendment: SEC Form 10-K/A filed by Serina Therapeutics Inc.
- SEC Form S-8 filed by Serina Therapeutics Inc.
- Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
- Serina Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits